openPR Logo
Press release

Ovarian Cancer - Pipeline Review, H2 2016, Pharmaceutical and Healthcare

01-04-2017 11:38 AM CET | Health & Medicine

Press release from: Ovarian Cancer

Ovarian Cancer - Pipeline Review, H2 2016, Pharmaceutical

"Ovarian Cancer - Pipeline Review, H2 2016" The Report covers current Market Trends, Worldwide Analysis, Global Forecast, Review, Share, Size, Growth, Effect.

Description-

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ovarian Cancer Pipeline Review, H2 2016, provides an overview of the Ovarian Cancer (Oncology) pipeline landscape.

Ovarian cancer is any cancerous growth that may occur in different parts of the ovary. The majority of ovarian cancers arise from the epithelium (outer lining) of the ovary. Signs and symptoms of ovarian cancer include pelvic discomfort or pain, indigestion, gas or nausea, changes in bowel habits, such as constipation, loss of appetite and low back pain. The predisposing factors include age and family history. Treatment includes surgery, chemotherapy and radiation therapy.

Get Sample Report With TOC @ https://goo.gl/JxlsyO

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ovarian Cancer Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Ovarian Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ovarian Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ovarian Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 2, 15, 115, 119, 7, 195, 31 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 11, 11, 34 and 8 molecules, respectively.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Ovarian Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Ovarian Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ovarian Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ovarian Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ovarian Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ovarian Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ovarian Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Researchmoz Global Pvt. Ltd.
90 State Street,
Albany, NY 12207,
United States,
Tel: 866-997-4948 (Us-Canada Toll Free),
Tel: +1-518-621-2074

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Ovarian Cancer - Pipeline Review, H2 2016, Pharmaceutical and Healthcare here

News-ID: 405266 • Views:

More Releases from Ovarian Cancer

Ovarian Cancer - Identifying and Commercializing First-in-Class Innovation: Frontier Pharma
Ovarian Cancer - Identifying and Commercializing First-in-Class Innovation: Fron …
Researchmoz added Most up-to-date research on "Ovarian Cancer - Identifying and Commercializing First-in-Class Innovation: Frontier Pharma" to its huge collection of research reports. Ovarian cancer is the sixth most common cancer in females and it also has the highest mortality rate of gynecological cancers. The five-year survival rate is approximately 45%, although the disease is ultimately fatal in the majority of patients due to a high rate of recurrence. Surgery is
Ovarian Cancer - US Market Insights, Epidemiology and Market Forecast-2020
ALBANY, NY, April 6, 2017 : DelveInsights Ovarian Cancer - Market Insights, Epidemiology and Market Forecast-2020- US Reports provides an overview of the disease and global market size of the Ovarian Cancer for the United States. It also includes global historical and forecasted epidemiological data for the diagnosed incident cases of Ovarian Cancer from 2012-2020. According to DelveInsight, the forecasted patient population of Ovarian cancer will decrease at a CAGR
Recent Study on Ovarian Cancer Identifying and Commercializing First-in-Class In …
Researchmoz added Most up-to-date research on "Frontier Pharma: Ovarian Cancer - Identifying and Commercializing First-in-Class Innovation" to its huge collection of research reports. Ovarian cancer is the sixth most common cancer in females and it also has the highest mortality rate of gynecological cancers. The five-year survival rate is approximately 45%, although the disease is ultimately fatal in the majority of patients due to a high rate of recurrence. Surgery is
Therapeutics Development For Ovarian Cancer - Pipeline Insights, 2017
Therapeutics Development For Ovarian Cancer - Pipeline Insights, 2017
Researchmoz added Most up-to-date research on "Therapeutics Development For Ovarian Cancer - Pipeline Insights, 2017" to its huge collection of research reports. DelveInsights, Ovarian Cancer -Pipeline Insights, 2016, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under the category of Ovarian Cancer. Ovarian cancer is the sudden growth of the cells

All 5 Releases


More Releases for Oncology

Precision Oncology Market Top Companies Study - Laboratory Corporation of Americ …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Precision Oncology Market Size, Share & Trends Analysis Report By Product Type (Diagnostics, Therapeutics), By Cancer Type (Breast Cancer, Cervical Cancer, Prostate Cancer, Lung Cancer), By End-use (Hospitals & Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, and Healthcare Data Companies)- Market Outlook And Industry Analysis 2031" The global Precision Oncology market is estimated to reach over USD
Veterinary Oncology Market Report 2024 - Veterinary Oncology Market Size, Share …
"The Business Research Company recently released a comprehensive report on the Global Veterinary Oncology Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry. According to The Business Research Company's, The veterinary oncology market size
Hepatocellular Carcinoma Pipeline 2024 | Can-Fite BioPharma, Sinocelltech, AVEO …
DelveInsight, "Hepatocellular Carcinoma Pipeline Insight 2024" report provides comprehensive insights about 90+ companies and 95+ pipeline drugs in Hepatocellular Carcinoma pipeline landscape. It covers the Hepatocellular Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hepatocellular Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways from the Hepatocellular Carcinoma Pipeline
Oncology Clinical Trials Market: Collaboration and Innovation in Oncology Resear …
Allied Market Research analysts have recently conducted a comprehensive research study titled "Oncology Clinical Trials Market: Global Outlook and Forecast 2023-2030." The report provides detailed information and analysis on key players in the market, including PAREXEL International, PRA Health Sciences, Syneos Health, Medpace, Novotech, Pivotal, Novartis, Merck, Bristol Myers Squibb company, and F. Hoffmann-La Roche. The study offers an in-depth analysis that encompasses clear market definitions, classifications, manufacturing processes, cost
Hemato Oncology Testing Market Global Hemato Oncology Testing Market, Hemato Onc …
Global Hemato Oncology Testing Market Research report is an in-depth study of the market Analysis. Along with the most recent patterns and figures that uncovers a wide examination of the market offer. This report provides exhaustive coverage on geographical segmentation, latest demand scope, growth rate analysis with industry revenue and CAGR status. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study
Oncology Market Size to Hit $447.3 Billion by 2028 | Oncology Industry Forecast …
Market Overview: According to our experience research team, Oncology Market was valued at USD 283.5 Billion in 2021, and the global Oncology industry is projected to reach a value of USD 447.3 Billion by 2028, at a CAGR of 7.9% during the forecast period 2022-2028 Vantage Market Research is a collection of market research studies on several industries, such as Chemicals, semiconductors & Electronics, Food & Beverages Technology, Energy & Power, Agriculture,